Loading...
XNAS
HBIO
Market cap28mUSD
Jul 09, Last price  
6.23USD
1D
-0.80%
1Q
44.55%
Jan 2017
-79.57%
IPO
-89.18%
Name

Harvard Bioscience Inc

Chart & Performance

D1W1MN
XNAS:HBIO chart
P/E
P/S
0.32
EPS
Div Yield, %
Shrs. gr., 5y
2.81%
Rev. gr., 5y
-3.25%
Revenues
87m
-8.06%
76,181,00083,407,00088,049,00085,772,000108,179,000108,864,000111,171,000105,171,000108,663,000108,664,000104,521,000101,882,000120,774,000116,176,000102,100,000118,904,000113,335,000112,250,00094,135,00086,550,000
Net income
-57m
L+357.07%
-2,341,000-1,354,0001,673,0007,233,00019,015,0003,812,0002,370,000-1,830,0002,355,000-19,039,000-4,307,000-865,000-3,462,000-4,687,000-7,810,000-288,000-9,516,000-3,415,000-12,405,000-56,700,000
CFO
7m
+367.29%
8,356,00012,055,0009,202,00016,509,00012,293,0006,348,0008,062,0004,060,0004,351,000705,0005,383,0001,057,0002,344,0008,047,0009,331,0001,262,0001,152,00014,028,0001,440,0006,729,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
IPO date
Oct 21, 2013
Employees
436
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT